Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

Journal:

Journal of Clinical Oncology

Published:

2025-12-02

DOI:

10.1200/jco-24-02835

Affiliations:

28

Authors:

59

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	10.000000 10.000000	0.31
Johnson & Johnson, Switzerland, Switzerland	1.000000	0.03
Samsung Medical Center (SMC), South Korea	1.000000	0.03
Hospital and Cancer Center, CQU, China	1.000000	0.03
Hunan Cancer Hospital, China	1.000000	0.03
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.03
Stanford Medicine, United States of America (USA)	1.000000	0.03
Johnson & Johnson - Greece, Greece	1.000000	0.03
Johnson & Johnson Medical (China) Ltd., China	1.000000	0.03
The First Hospital of Jilin University, China	1.000000	0.03
Institute Gustave-Roussy (IGR), France	1.000000	0.03
Cancer Center, WCSM/WCH SCH, China	1.000000	0.03
Seoul National University Hospital (SNUH), South Korea	1.000000	0.03
Center for Integrated Oncology Aachen Bonn Köln Düsseldorf (CIO), Germany	1.000000	0.03
Virginia Cancer Specialists (VCS), United States of America (USA)	1.000000	0.03
Yonsei Cancer Hospital, South Korea	1.000000	0.03
Cancer Research Center of Marseille (CRCM), France	1.000000	0.03
National Taiwan University Hospital (NTUH), Taiwan	1.000000	0.03
University of Pennsylvania (Penn), United States of America (USA)	1.000000	0.03
Okayama University Hospital, Japan	1.000000	0.03
National Cancer Center Hospital East, Japan	1.000000	0.03
Vall d'Hebron University Hospital (HUVH), ICS, Spain	0.500000	0.02
Autonomous University of Barcelona (UAB), Spain	0.500000	0.02
University of Washington (UW), United States of America (USA)	0.500000	0.02
Fred Hutchinson Cancer Center, United States of America (USA)	0.500000	0.02

Interested in Oncology and Carcinogenesis?